New triple-hormone drug retatrutide leads to up to 25% weight loss in trial

Retatrutide, a novel obesity drug that simulates the hormones GLP-1, GIP, and glucagon, has shown promising results in clinical trials with participants losing up to 25% of their body weight. This development marks a significant advancement in obesity treatment options.

Originally published by arstechnica